Annals of the Rheumatic Diseases

Pui Y Lee, Grant S Schulert, Scott W Canna, Yuelong Huang, Jacob Sundel, Ying Li, Kacie J Hoyt, Rachel B Blaustein, Alexandra Wactor, Thuy Do, Olha Halyabar, Margaret H Chang, Fatma Dedeoglu, Siobhan M Case, Esra Meidan, Mindy S Lo, Robert P Sundel, Edward T Richardson, Jane W Newburger, Michael S Hershfield, Mary Beth Son, Lauren A Henderson, Peter A Nigrovic
OBJECTIVE: Macrophage activation syndrome (MAS) is a life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) characterised by a vicious cycle of immune amplification that can culminate in overwhelming inflammation and multiorgan failure. The clinical features of MAS overlap with those of active sJIA, complicating early diagnosis and treatment. We evaluated adenosine deaminase 2 (ADA2), a protein of unknown function released principally by monocytes and macrophages, as a novel biomarker of MAS...
November 9, 2019: Annals of the Rheumatic Diseases
Christina Adamichou, Dionysis Nikolopoulos, Irini Genitsaridi, Alessandra Bortoluzzi, Antonis Fanouriakis, Emmanouil Papastefanakis, Eleni Kalogiannaki, Irini Gergianaki, Prodromos Sidiropoulos, Dimitrios T Boumpas, George K Bertsias
OBJECTIVES: Classification criteria are biased towards classifying long-standing disease. We compared the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR)-2019, Systemic Lupus International Collaborating Clinics (SLICC)-2012 and ACR-1997 criteria in an early (median 48 months) systemic lupus erythematosus (SLE) cohort. METHODS: Patients diagnosed with SLE (n=690) or control diseases (n=401). Sensitivity, specificity of the criteria and time-to-classification were calculated...
November 8, 2019: Annals of the Rheumatic Diseases
Petrus Linge, Sabine Arve, Lina M Olsson, Dag Leonard, Christopher Sjöwall, Martina Frodlund, Iva Gunnarsson, Elisabet Svenungsson, Helena Tydén, Andreas Jönsen, Robin Kahn, Åsa Johansson, Lars Rönnblom, Rikard Holmdahl, Anders Bengtsson
​OBJECTIVES: A single nucleotide polymorphism in the NCF1 gene (NCF1-339, rs201802880), encoding NADPH oxidase type II subunit NCF1/p47phox , reducing production of reactive oxygen species (ROS) is strongly associated with the development of systemic lupus erythematosus (SLE). This study aimed at characterising NCF1-339 effects on neutrophil extracellular trap (NET) formation, type I interferon activity and antibody profile in patients with SLE. ​METHODS: Neutrophil NET-release pathways (n=31), serum interferon (n=141) and finally antibody profiles (n=305) were investigated in SLE subjects from Lund, genotyped for NCF1-339...
November 8, 2019: Annals of the Rheumatic Diseases
Toshihiro Kishikawa, Yuichi Maeda, Takuro Nii, Daisuke Motooka, Yuki Matsumoto, Masato Matsushita, Hidetoshi Matsuoka, Maiko Yoshimura, Shoji Kawada, Satoru Teshigawara, Eri Oguro, Yasutaka Okita, Keisuke Kawamoto, Shinji Higa, Toru Hirano, Masashi Narazaki, Atsushi Ogata, Yukihiko Saeki, Shota Nakamura, Hidenori Inohara, Atsushi Kumanogoh, Kiyoshi Takeda, Yukinori Okada
OBJECTIVE: The causality and pathogenic mechanism of microbiome composition remain elusive in many diseases, including autoimmune diseases such as rheumatoid arthritis (RA). This study aimed to elucidate gut microbiome's role in RA pathology by a comprehensive metagenome-wide association study (MWAS). METHODS: We conducted MWAS of the RA gut microbiome in the Japanese population ( n case =82, n control =42) by using whole-genome shotgun sequencing of high depth (average 13 Gb per sample)...
November 7, 2019: Annals of the Rheumatic Diseases
Johannes Mofors, Albin Björk, Karin E Smedby, Marika Kvarnström, Helena Forsblad-d'Elia, Sara Magnusson-Bucher, Per Eriksson, Thomas Mandl, Eva Baecklund, Gunnel Nordmark, Marie Wahren-Herlenius
No abstract text is available yet for this article.
November 6, 2019: Annals of the Rheumatic Diseases
Masatoshi Jinnin, Akiko Ohta, Shoichiro Ishihara, Hirofumi Amano, Tatsuya Atsumi, Manabu Fujimoto, Takashi Kanda, Yasushi Kawaguchi, Atsushi Kawakami, Akio Mimori, Tsuneyo Mimori, Toshihide Mimura, Yoshinao Muro, Hajime Sano, Jun Shimizu, Tsutomu Takeuchi, Yoshiya Tanaka, Kazuhiko Yamamoto, Takayuki Sumida, Hitoshi Kohsaka
OBJECTIVE: To externally validate the performance of the new European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria set for idiopathic inflammatory myopathies (IIM) with a Japanese cohort. METHODS: This study included 420 IIM and 402 non-IIM cases. Probability of having IIM in each patient was calculated using the collected data set. The cut-off probability was set at 55%, as recommended by EULAR/ACR. Patients classified as IIM by the criteria were further subclassified with classification trees...
November 6, 2019: Annals of the Rheumatic Diseases
Gerasimos Evangelatos, George E Fragoulis, Alexios Iliopoulos
No abstract text is available yet for this article.
November 5, 2019: Annals of the Rheumatic Diseases
Maxime Dougados, James Cheng-Chung Wei, Robert Landewé, Joachim Sieper, Xenofon Baraliakos, Filip Van den Bosch, Walter P Maksymowych, Joerg Ermann, Jessica A Walsh, Tetsuya Tomita, Atul Deodhar, Désirée van der Heijde, Xiaoqi Li, Fangyi Zhao, Clinton C Bertram, Gaia Gallo, Hilde Carlier, Lianne S Gensler
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive (COAST-V) or tumour necrosis factor inhibitor (TNFi)-experienced (COAST-W). METHODS: Adults with active r-axSpA were randomised 1:1:1:1 (n=341) to 80 mg ixekizumab every 2 (IXE Q2W) or 4 weeks (IXE Q4W), placebo (PBO) or 40 mg adalimumab Q2W (ADA) in COAST-V and 1:1:1 (n=316) to IXE Q2W, IXE Q4W or PBO in COAST-W...
November 4, 2019: Annals of the Rheumatic Diseases
Amit Saxena, Peter M Izmirly, Rebecca P Bomar, Rachel Shireen Golpanian, Deborah M Friedman, Ruth Eisenberg, Mimi Y Kim, Jill P Buyon
OBJECTIVES: Cardiac manifestations of neonatal lupus (NL) have been associated with significant morbidity and mortality; however, there is minimal information on long-term outcomes of affected individuals. This study was initiated to evaluate the presence of and the risk factors associated with cardiac dysfunction in NL after birth in multiple age groups to improve counselling, to further understand pathogenesis and to provide potential preventative strategies. METHODS: Echocardiogram reports were evaluated in 239 individuals with cardiac NL: 143 from age 0-1 year, 176 from age >1-17 years and 64 from age >17 years...
October 31, 2019: Annals of the Rheumatic Diseases
Manuel Ramos-Casals, Pilar Brito-Zerón, Stefano Bombardieri, Hendrika Bootsma, Salvatore De Vita, Thomas Dörner, Benjamin A Fisher, Jacques-Eric Gottenberg, Gabriela Hernandez-Molina, Agnes Kocher, Belchin Kostov, Aike A Kruize, Thomas Mandl, Wan-Fai Ng, Soledad Retamozo, Raphaèle Seror, Yehuda Shoenfeld, Antoni Sisó-Almirall, Athanasios G Tzioufas, Claudio Vitali, Simon Bowman, Xavier Mariette
The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target beyond the relief of symptoms as the most important goal. In view of this scenario, the European League Against Rheumatism (EULAR) promoted and supported an international collaborative study (EULAR SS Task Force) aimed at developing the first EULAR evidence and consensus-based recommendations for the management of patients with SjS with topical and systemic medications...
October 31, 2019: Annals of the Rheumatic Diseases
Xintong Li, Kathleen M Andersen, Hsien-Yen Chang, Jeffrey R Curtis, G Caleb Alexander
OBJECTIVE: To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients. METHODS: We assembled a retrospective cohort of commercially insured adults in the USA diagnosed with PsO or PsA between 2015 and 2018. Exposure was dispensation for IL-17 (ixekizumab or secukinumab), IL-12/23 (ustekinumab) or TNF (adalimumab, certolizumab pegol, etanercept, golimumab and infliximab)...
October 31, 2019: Annals of the Rheumatic Diseases
Edward Roddy, Kris Clarkson, Milica Blagojevic-Bucknall, Rajnikant Mehta, Raymond Oppong, Anthony Avery, Elaine M Hay, Carl Heneghan, Liz Hartshorne, Julie Hooper, Gemma Hughes, Sue Jowett, Martyn Lewis, Paul Little, Karen McCartney, Kamal R Mahtani, David Nunan, Miriam Santer, Sam Williams, Christian D Mallen
OBJECTIVES: To compare the effectiveness and safety of naproxen and low-dose colchicine for treating gout flares in primary care. METHODS: This was a multicentre open-label randomised trial. Adults with a gout flare recruited from 100 general practices were randomised equally to naproxen 750 mg immediately then 250 mg every 8 hours for 7 days or low-dose colchicine 500 mcg three times per day for 4 days. The primary outcome was change in worst pain intensity in the last 24 hours (0-10 Numeric Rating Scale) from baseline measured daily over the first 7 days: mean change from baseline was compared between groups over days 1-7 by intention to treat...
October 30, 2019: Annals of the Rheumatic Diseases
Kevin L Winthrop, Michael E Weinblatt, Joan Bathon, Gerd R Burmester, Philip J Mease, Leslie Crofford, Vivian Bykerk, Maxime Dougados, James Todd Rosenbaum, Xavier Mariette, Joachim Sieper, Fritz Melchers, Bruce N Cronstein, Ferry C Breedveld, Joachim Kalden, Josef S Smolen, Daniel Furst
OBJECTIVES: To detail the greatest areas of unmet scientific and clinical needs in rheumatology. METHODS: The 21st annual international Advances in Targeted Therapies meeting brought together more than 100 leading basic scientists and clinical researchers in rheumatology, immunology, epidemiology, molecular biology and other specialties. During the meeting, breakout sessions were convened, consisting of 5 disease-specific groups with 20-30 experts assigned to each group based on expertise...
October 29, 2019: Annals of the Rheumatic Diseases
Gary J Macfarlane, Ovidiu Rotariu, Gareth T Jones, Ejaz Pathan, Linda E Dean
OBJECTIVE: To determine modifiable factors associated with poor quality of life (QoL) in patients with axial spondyloarthritis (axSpA). METHODS: Analysis of data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) and validation of a previous model using data from 1810 patients with axSpA recruited during 2012-2017. Data collected included clinical and patient-reported measures. QoL was assessed using the Ankylosing Spondylitis Quality of Life (ASQoL) measure...
October 29, 2019: Annals of the Rheumatic Diseases
Elke G E Mathijssen, Johanna E Vriezekolk, Calin D Popa, Bart J F van den Bemt
OBJECTIVES: Although shared decision making (SDM) is advocated in rheumatoid arthritis (RA) treatment, it is largely unclear when, how and to what extent SDM is applied in routine clinical care of patients with RA. This study aimed to investigate the level of SDM in RA treatment from an observer perspective and to assess associations between the level of SDM and characteristics of the clinician, patient and consultation. METHODS: The level of SDM was investigated by scoring audio-recordings of 168 routine consultations with unique patients with the observer patient involvement (OPTION) scale (scale 0-100, higher OPTION scores indicating higher levels of SDM)...
October 29, 2019: Annals of the Rheumatic Diseases
Liang Kuang, Jiangyi Wu, Nan Su, Huabing Qi, Hangang Chen, Siru Zhou, Yan Xiong, Xiaolan Du, Qiaoyan Tan, Jing Yang, Min Jin, Fengtao Luo, Junjie Ouyang, Bin Zhang, Zuqiang Wang, Wanling Jiang, Liang Chen, Shuai Chen, Ziming Wang, Peng Liu, Liangjun Yin, Fengjin Guo, Chuxia Deng, Di Chen, Chuanju Liu, Yangli Xie, Zhenhong Ni, Lin Chen
OBJECTIVES: This study aims to investigate the role and mechanism of FGFR3 in macrophages and their biological effects on the pathology of arthritis. METHODS: Mice with conditional knockout of FGFR3 in myeloid cells (R3cKO) were generated. Gait behaviours of the mice were monitored at different ages. Spontaneous synovial joint destruction was evaluated by digital radiographic imaging and μCT analysis; changes of articular cartilage and synovitis were determined by histological analysis...
October 29, 2019: Annals of the Rheumatic Diseases
Jian Yin, Peter Richard Sternes, Mingbang Wang, Jing Song, Mark Morrison, Ting Li, Ling Zhou, Xin Wu, Fusheng He, Jian Zhu, Matthew A Brown, Huji Xu
OBJECTIVES: Diverse evidence including clinical, genetic and microbiome studies support a major role of the gut microbiome in the common immune-mediated arthropathy, ankylosing spondylitis (AS). We set out to (1) further define the key microbial characteristics driving disease, and (2) examine the effects of tumour necrosis factor-inhibitor (TNFi) therapy upon the microbiome. METHODS: The stools from a case-control cohort of 250 Han-Chinese subjects underwent shotgun metagenomic sequencing...
October 29, 2019: Annals of the Rheumatic Diseases
Shih-Wei Lai
No abstract text is available yet for this article.
October 25, 2019: Annals of the Rheumatic Diseases
Michael Leutner, Caspar Matzhold, Luise Bellach, Carola Deischinger, Jürgen Harreiter, Stefan Thurner, Peter Klimek, Alexandra Kautzky-Willer
No abstract text is available yet for this article.
October 25, 2019: Annals of the Rheumatic Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"